RDY
Income statement / Annual
Last year (2025), Dr. Reddy's Laboratories Limited's total revenue was $325.54 B,
an increase of 16.61% from the previous year.
In 2025, Dr. Reddy's Laboratories Limited's net income was $56.54 B.
See Dr. Reddy's Laboratories Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$325.54 B |
$279.16 B |
$245.88 B |
$214.39 B |
$2.56 B |
$174.60 B |
$153.85 B |
$142.03 B |
$140.81 B |
$154.71 B |
| Cost of Revenue |
$135.11 B
|
$115.56 B
|
$106.54 B
|
$100.55 B
|
$1.26 B
|
$80.59 B
|
$70.42 B
|
$65.72 B
|
$62.45 B
|
$62.43 B
|
| Gross Profit |
$190.43 B
|
$163.61 B
|
$139.34 B
|
$113.84 B
|
$1.30 B
|
$94.01 B
|
$83.43 B
|
$76.30 B
|
$78.36 B
|
$92.28 B
|
| Gross Profit Ratio |
0.58
|
0.59
|
0.57
|
0.53
|
0.51
|
0.54
|
0.54
|
0.54
|
0.56
|
0.6
|
| Research and Development Expenses |
$27.38 B
|
$22.87 B
|
$19.38 B
|
$17.48 B
|
$208.37 M
|
$15.41 B
|
$15.61 B
|
$18.27 B
|
$19.55 B
|
$17.83 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$93.87 B
|
$77.20 B
|
$68.03 B
|
$62.08 B
|
$659.90 M
|
$0.00
|
$48.89 B
|
$46.91 B
|
$46.37 B
|
$45.70 B
|
| Other Expenses |
-$2.67 B
|
-$4.20 B
|
-$5.21 B
|
$4.80 B
|
$1.91 M
|
$62.61 B
|
-$691.00 M
|
-$843.00 M
|
-$1.15 B
|
-$986.00 M
|
| Operating Expenses |
$118.59 B
|
$95.88 B
|
$82.20 B
|
$84.36 B
|
$866.36 M
|
$78.02 B
|
$62.54 B
|
$64.39 B
|
$64.86 B
|
$62.66 B
|
| Cost And Expenses |
$253.69 B
|
$211.44 B
|
$188.74 B
|
$184.92 B
|
$2.12 B
|
$158.61 B
|
$132.96 B
|
$130.11 B
|
$127.31 B
|
$125.09 B
|
| Interest Income |
$2.68 B
|
$2.28 B
|
$1.18 B
|
$965.00 M
|
$826.00 M
|
$12.59 M
|
$770.00 M
|
$540.00 M
|
$558.00 M
|
$1.40 B
|
| Interest Expense |
$2.83 B
|
$1.71 B
|
$1.43 B
|
$958.00 M
|
$970.00 M
|
$13.86 M
|
$889.00 M
|
$788.00 M
|
$634.00 M
|
$826.00 M
|
| Depreciation & Amortization |
$17.06 B
|
$14.84 B
|
$12.64 B
|
$11.82 B
|
$172.37 M
|
$12.47 B
|
$12.19 B
|
$11.71 B
|
$11.28 B
|
$10.25 B
|
| EBITDA |
$96.67 B |
$88.42 B |
$74.43 B |
$45.08 B |
$534.77 M |
$41.79 B |
$35.52 B |
$23.74 B |
$24.55 B |
$40.18 B |
| EBITDA Ratio |
0.3
|
0.32
|
0.3
|
0.21
|
0.21
|
0.24
|
0.23
|
0.17
|
0.17
|
0.26
|
| Operating Income Ratio |
0.22
|
0.24
|
0.23
|
0.14
|
0.17
|
0.09
|
0.14
|
0.08
|
0.1
|
0.19
|
| Total Other Income/Expenses Net |
$4.94 B
|
$4.14 B
|
$3.22 B
|
$2.82 B
|
-$75.64 M
|
$2.04 B
|
$1.56 B
|
$2.42 B
|
$1.16 B
|
-$2.48 B
|
| Income Before Tax |
$76.78 B
|
$71.87 B
|
$60.37 B
|
$32.30 B
|
$355.80 M
|
$18.03 B
|
$22.44 B
|
$14.34 B
|
$14.65 B
|
$27.14 B
|
| Income Before Tax Ratio |
0.24
|
0.26
|
0.25
|
0.15
|
0.14
|
0.1
|
0.15
|
0.1
|
0.1
|
0.18
|
| Income Tax Expense |
$19.54 B
|
$16.19 B
|
$15.30 B
|
$8.73 B
|
$123.59 M
|
-$1.47 B
|
$3.65 B
|
$4.54 B
|
$2.61 B
|
$7.13 B
|
| Net Income |
$56.54 B
|
$55.68 B
|
$45.07 B
|
$23.57 B
|
$232.21 M
|
$19.50 B
|
$18.80 B
|
$9.81 B
|
$12.04 B
|
$20.01 B
|
| Net Income Ratio |
0.17
|
0.2
|
0.18
|
0.11
|
0.09
|
0.11
|
0.12
|
0.07
|
0.09
|
0.13
|
| EPS |
67.85 |
66.8 |
54.29 |
28.42 |
20.79 |
117.63 |
113.28 |
59.13 |
72.24 |
117.34 |
| EPS Diluted |
67.77 |
66.8 |
54.17 |
28.34 |
20.73 |
117.4 |
113.09 |
59.01 |
72.09 |
116.98 |
| Weighted Average Shares Out |
$833.31 M
|
$833.54 M
|
$830.17 M
|
$829.41 M
|
$829.22 M
|
$828.79 M
|
$829.58 M
|
$829.19 M
|
$833.24 M
|
$852.74 M
|
| Weighted Average Shares Out Diluted |
$834.30 M
|
$833.54 M
|
$831.91 M
|
$831.69 M
|
$831.58 M
|
$830.41 M
|
$830.98 M
|
$830.93 M
|
$834.99 M
|
$855.36 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
